Blog | Veristat Insightful Perspectives

Is Your Complex NDA/MAA Submission Missing One of These Key Elements?

By Martha Plaza, MBA; Amanda Truesdale, MA, MBA; and Kimberly Newton, MA. 

Read More

Key Strategies for Overcoming Data Analysis Difficulties During NDA/MAA Submissions

By Amanda Truesdale, MA, MBA, VP Biometrics

When database locks are delayed, or regulatory agencies request additional analyses for new drug applications (NDAs) or marketing authorization applications (MAAs), it seems there is no alternative but to take a hit to the timeline — or is there?

Read More

Flexibility is the Key to Data Acquisition for Rare Disease Trials

Understanding Why Creative Data Collection Solutions Are Necessary

Read More